Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)

    NIH supports later-stage research and development for previously funded small business Phase II projects, bridging the gap to commercialization.

    OverviewSimilar Grants
    OverviewSimilar Grants

    NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)

    Supports U.S. small businesses in bringing scientific innovations to market through feasibility studies and later research and development, with clinical trials optional.

    HHS-NIH11Due Jan 5, 2027$3,000,000

    SBIR/STTR Phase IIB Supplemental Funding Requests

    The NSF SBIR/STTR Phase IIB supplement matches external capital to help Phase II awardees accelerate R&D and commercialization of innovative technologies.

    NSFRolling submissions$500,000

    Small Business Innovation Research (SBIR) program, Phase I

    Phase I grants support small businesses in testing the feasibility of research and development ideas that could improve the lives of people with disabilities; 11 six-month grants are available.

    HHS-ACLForecasted Dec 16, 2026$100,000Forecasted

    Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs SBIR/STTR: Developing Deep Technologies that Advance U.S. Competitiveness and Security

    SBIR/STTR Phase I, Phase II, and Fast-Track Programs support startups and small businesses developing high-risk deep technologies into commercial products and services to advance U.S. competitiveness and security.

    NSFDue Mar 4, 2027$30,000,000

    Small Business Innovation Research Program (SBIR) Phase II

    Four 24-month Phase II grants support small businesses developing products that improve health, community living, or employment outcomes for people with disabilities.

    HHS-ACLForecasted Feb 1, 2027$287,500Forecasted